“Origami” DNA Traps Could Keep Large Viruses From Infecting Cells
By engineering structures out of DNA, scientists could potentially prevent larger viruses, like coronaviruses and influenza viruses, from interacting with cells.
“Origami” DNA Traps Could Keep Large Viruses From Infecting Cells
“Origami” DNA Traps Could Keep Large Viruses From Infecting Cells
By engineering structures out of DNA, scientists could potentially prevent larger viruses, like coronaviruses and influenza viruses, from interacting with cells.
By engineering structures out of DNA, scientists could potentially prevent larger viruses, like coronaviruses and influenza viruses, from interacting with cells.
This year, cancer researchers uncovered a variety of ways that tumors can survive and spread, ranging from damaging their own DNA to exploiting the nearby microenvironment for nutrients.
A clinical trial finds that the anticoagulant apixaban, which has been prescribed to help COVID-19 patients recover, is ineffective and in rare instances dangerous.
Thanks to continued weekly medications, a 16-month-old girl shows no symptoms of a severe genetic disease that typically kills children before they turn two.
Both Pfizer and GSK have shared preliminary data suggesting that their experimental vaccines can protect older adults and newborn infants from the virus.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
A protein duo increases transcription of growth-related genes to enhance axon regeneration and boost plasticity, a study finds—but fails to improve mobility.
A Stone Age individual’s left leg healed after being amputated just above the foot, allowing them to survive for six to nine years after the procedure was performed, researchers say.
Evidence thus far shows that pregnant people infected with SARS-CoV-2 are at higher risk for severe disease and death, as well as complications in their pregnancies.
BA.2.75 is spreading rampantly in India and has so far reached at least 20 other countries, but it doesn’t seem to be outcompeting other Omicron SARS-CoV-2 subvariants.
Thenewly authorized intradermal vaccination only requires one-fifth of the usual vaccine dose. This will help stretch out the limited vaccine supply, experts say, but only if healthcare personnel receive sufficient training.
Studies show that a fourth mRNA vaccine dose offers the elderly and other high-risk groups strong protection against hospitalization and death from COVID-19, but experts say benefits for other populations may be more limited.